Utility of intravoxel incoherent motion diffusion-weighted imaging in predicting pathological response to neoadjuvant immuno-chemotherapy for locally advanced gastric cancer

Gastric cancer, or stomach cancer, is a formidable disease that often requires a multi-step approach to treat effectively. For patients with locally advanced disease, where the tumor has grown deep into the stomach wall but has not yet spread to distant organs, doctors typically begin with treatment before surgery. This pre-surgical phase, known as neoadjuvant therapy, aims to shrink the tumor and kill cancer cells early on. In recent years, a powerful new combination has emerged: pairing traditional chemotherapy with immunotherapy. This approach, called neoadjuvant immuno-chemotherapy, has shown promise in helping more patients achieve a complete response, meaning the cancer disappears entirely from the surgical specimen. However, not every patient responds to this treatment in the same way. Some see their tumors shrink dramatically, while others see little change. Currently, the only way to know for sure if the treatment worked is to wait until after the stomach is surgically removed and a pathologist examines the tissue under a microscope. This delay means that patients who are not responding to the drugs continue to receive them, potentially suffering side effects without benefit, while missing the chance to switch to a different strategy sooner.

To solve this problem, researchers at Henan Cancer Hospital in China set out to find a way to predict treatment success before the surgery even takes place. They turned to a specialized type of magnetic resonance imaging, or MRI, that looks beyond the shape of the tumor to see how water molecules move inside it. In healthy tissue, water moves freely, but in cancer, the cells are packed so tightly that water struggles to get through. This technique, known as diffusion-weighted imaging, can measure this movement. The researchers used an advanced version of this scan called intravoxel incoherent motion, or IVIM. While standard scans give a single number describing how restricted the water is, IVIM splits the signal into two parts: one that measures the actual movement of water through the tissue, and another that measures the tiny, random movements caused by blood flowing through the smallest vessels. By looking at both of these signals, the team hoped to create a clearer picture of what was happening inside the tumor at a cellular level.

The study followed ninety-three patients with locally advanced gastric cancer who were scheduled to receive the new immuno-chemotherapy treatment followed by surgery. Before the first dose of medication, each patient underwent a detailed MRI scan. The researchers carefully measured the movement of water and blood flow within the tumors. After the patients completed their treatment and underwent surgery, pathologists examined the removed stomachs to determine how much the cancer had regressed. They classified the patients into two groups: those who responded well to the treatment, showing significant tumor shrinkage or disappearance, and those who did not respond, where the cancer remained largely unchanged.

When the researchers compared the MRI scans taken before treatment with the final pathology results, a clear pattern emerged. The patients who did not respond to the therapy had tumors where water moved much more slowly than in the responders, indicating extremely dense cell packing. Furthermore, these non-responding tumors showed a higher fraction of blood flow-related movement, suggesting a different kind of vascular activity that might be shielding the cancer cells from the drugs. In contrast, the patients who responded well had tumors where water moved more freely and the blood flow signal was lower. The researchers found that looking at just one of these measurements was helpful, but combining the data on water movement and blood flow created a much more accurate predictor. This combined approach correctly identified the non-responders about 78 percent of the time, a significant improvement over using any single measurement alone.

The study also looked at what happened to these patients after their surgery. Those who were identified as high-risk for not responding based on their initial MRI scans had a shorter time before their disease returned or spread compared to those who were identified as low-risk. This suggests that the scan does not just predict the immediate reaction to the drugs but also offers a glimpse into the long-term outlook for the patient. The researchers noted that while the technique showed great promise, it is not yet a perfect tool. The study was relatively small, and the specific settings used for the MRI scans were unique to their hospital, meaning the results need to be tested in larger groups of patients and different medical centers to confirm they work universally.

Ultimately, this work suggests that doctors may soon have a way to see inside a tumor's biology before starting a grueling course of treatment. Instead of waiting months to find out if a drug is working, a simple MRI scan could reveal whether the cancer is likely to resist the therapy. If a patient's scan indicates a poor response, doctors could potentially stop the ineffective treatment early and move to a different strategy, sparing the patient from unnecessary side effects and giving them a better chance at a successful outcome. While the technology is still in the testing phase, the ability to distinguish between a tumor that will vanish and one that will persist offers a tangible step toward more personalized and effective care for stomach cancer.